TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Lumbar spine projected area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in prostate specific antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Function of respiratory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hypovolaemic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative trichiasis rates (PTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antigen-specific B and T cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination numbers of plasma B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Responsiveness to recall challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: linked partner infections
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity for IHC versus FISH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of an occluded infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-day incidence of cardiovascular death, recurrent MI or recurrent myocardial ischemia requiring urgent revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Peak hyperemic response to forearm ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Recurrence rate of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of force development (RTD) of the plantar flexors during MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short and mid term memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of verbal cues required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of physical cues required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in systematic examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting high grade CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for detecting high grade CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handling-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in maximum standardized uptake value (SUV(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total % time pH < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improved quality‐of‐life measures for GERD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cessation of dependence on PPIs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prostatic symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostatic symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAD depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Menstrual rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interdialytic Weight Gain (IWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure episodes (hyper- and hypotensive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of the language of mental states and intentions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achievement of ASAS20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in CES-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IFN-antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reappearance of HCV-RNA during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative incidence of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women being offered and accepting membrane sweeping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Average number of sweeps per woman
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: memory certainty for negative social stimuli
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: post-operative serum creatinine (sCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: initiation of dialysis
Endpoint domain: Adverse events/effects
Primary endpoint: Epicardial diameter response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood flow response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in use of 'is'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remaining ratio of peptic ulcers after 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complete healing rate after 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ED50 values for edrophonium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent olfactory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients reporting severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving RVNA titer of ≥0.5 IU/mL by Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RVNA geometric mean titer at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time to reach RVNA titer of ≥0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of the diagnostic model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the diagnostic model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength of Clearfil cement to zirconia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature failures in zirconia surfaces
Endpoint domain: Adverse events/effects
Primary endpoint: number of trajectory mistakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body mass index Z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Riboflavin absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of severe itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of reactive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of relapsed patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hematologic toxicities (grade 3/4)
Endpoint domain: Adverse events/effects
Primary endpoint: VLSC symptom-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in high‐sensitivity C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in N‐terminal prohormone of brain natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspirin-triggered 15-epi-lipoxin A4 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General tolerability of vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: hypokalemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: DLco (Diffusing capacity of the lungs for carbon monoxide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of purpura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: red blood cell deformability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximal walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interobserver agreement for volume data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-observer agreement for volume data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in reaching the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PM performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of Life (QoL) variation patterns
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Personal-social score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: IgG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mental Component Summary (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical signs of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of cardiovascular disease
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing ARI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of self-collected nasal swabs for influenza detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptability of self-collection of nasal swabs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of DMN connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: confirmed awareness
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of specific adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pulsatility index of the ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of belimumab IV and SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-QoL score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ischemic stroke rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success rate at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: quality of life decrease at 4 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gingival index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement quality (optimum, acceptable, unacceptable)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined endpoint of ischemic stroke, coronary disease, or death
Endpoint domain: Mortality/survival
Primary endpoint: Improved survival at five years
Endpoint domain: Mortality/survival
Primary endpoint: Improved survival at twelve years
Endpoint domain: Mortality/survival
Primary endpoint: Amplitudes of PCES-EP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of BRCA1/2 test results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specific immunoglobulin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific immunoglobulin G4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and accuracy of ATP stress 201Tl SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PG D2-induced nasal blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cryo-survival rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Child BMI z-score at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: VAS (the back and leg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MacNab score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean healthcare cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean number of ADR events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted mean differences in PPG (AUC1-4h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjusted mean differences in 24-hour mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time with glucose ≥70 to <180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery of eustachian tube function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Böhler's angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in clinical remission at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with histologic remission at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of ENDSICH
Endpoint domain: Adverse events/effects
Primary endpoint: Follicle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular maturation stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score (DAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total accumulative score of adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in speech function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady decline in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain score (FLACC scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of rescue medicine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time without symptoms and toxicity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenohumeral joint mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peak GH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: specificity of the ITT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of anti-gE geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: absence of psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of substance use disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uroflowmetry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in visual analogue scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance/MRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mental Component Summary score change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in PDsGaw35
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HAMD and SDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma level of endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma level of IL-1 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma level of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma level of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC of carbamazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax/AUC of carbamazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary prevention of cancer-associated VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: QTcN prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal PCr reperfusion signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak BOLD signal during reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived facility availability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived home equipment availability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: actuarial survival rate without evidence of disease
Endpoint domain: Mortality/survival
Primary endpoint: Mood-enhancing effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnosis of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of low-risk prostate cancer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: quit attempts
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of fecal incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to postpone defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year freedom from recurrence of significant mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year freedom from reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prostate Specific Antigen Doubling Time (PSADT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lower incisors position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mandibular first molars position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in theatre recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenal function suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained control of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Hepatitis B e antigen (HBeAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes